No abstract

No abstract

The authors propose that cultural frame shifting—shifting between two culturally based interpretative lenses in response to cultural cues—is moderated by perceived compatibility (vs. opposition) between the two cultural orientations, or bicultural identity integration (BII). Three studies found that Chinese American biculturals who perceived their cultural identities as compatible (high BII) responded in culturally congruent ways to cultural cues: They made more external attributions (a characteristically Asian behavior) after being exposed to Chinese primes and more internal attributions (a characteristically Western behavior) after being exposed to American primes. However, Chinese American biculturals who perceived their cultural identities as oppositional (low BII) exhibited a reverse priming effect. This trend was not apparent for noncultural primes. The results show that individual differences in bicultural identity affect how cultural knowledge is used to interpret social events.

The effect of ACE inhibition on the formation of advanced glycation end products (AGEs) and oxidative stress was explored. Streptozocin-induced diabetic animals were randomized to no treatment, the ACE inhibitor ramipril (3 mg/l), or the AGE formation inhibitor aminoguanidine (1 g/l) and followed for 12 weeks. Control groups were followed concurrently. Renal AGE accumulation, as determined by immunohistochemistry and both serum and renal fluorescence, were increased in diabetic animals. This was attenuated by both ramipril and aminoguanidine to a similar degree. Nitrotyrosine, a marker of protein oxidation, also followed a similar pattern. The receptor for AGEs, gene expression of the membrane-bound NADPH oxidase subunit gp91phox, and nuclear transcription factor-kappaB were all increased by diabetes but remained unaffected by either treatment regimen. Two other AGE receptors, AGE R2 and AGE R3, remained unchanged for the duration of the study. The present study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic nephropathy that may be linked through oxidative stress

This article examines how multiracial individuals negotiate their different and sometimes conflicting racial identities. Drawing from previous work on bicultural identity integration (see Benet-Martínez & Haritatos, 2005), we proposed a new construct, multiracial identity integration (MII), to measure individual differences in perceptions of compatibility between multiple racial identities. We found that MII is composed of two independent subscales: racial distance that describes whether different racial identities are perceived as disparate, and racial conflict that describes whether different racial identities are perceived as in conflict. We also found that recalling positive multiracial experiences increased MII, while recalling negative multiracial experiences decreased MII. These findings have implications for understanding the psychological well-being of multiracial individuals, and the development of social policy and programs catered to this population.

Proactivelyseeking help from others involves “social costs” because the help seeker appears incompetent, dependent, and inferior to others. This article hypothesizes that these costs are especially threatening when the help seeker is male and in a male-oriented occupational role, when the helper is in a higher or lower status role than the help seeker, and when the task is novel and central to the organization’s core competence. A field study examined physician and nurse help seeking regarding a new computer system within a large hospital. The results showed that individuals reported less help seeking when theywere male, in male-oriented occupations, and when the task was central to the organization’s core competence. Perceived social costs mediated these effects.

Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders. Two double-blind, randomized, and placebo-controlled studies were conducted to evaluate single ascending doses of 1-20 mg and multiple ascending doses of 2-20 mg QD and 5 mg BID for 10 or 28 days in healthy volunteers. Following oral administration, baricitinib plasma concentration typically attains its peak value within 1.5 hours postdose and subsequently declines in a bi-exponential fashion. Baricitinib demonstrates dose-linear and time-invariant pharmacokinetics, with low oral-dose clearance (17 L/h) and minimal systemic accumulation observed following repeat dosing. The mean renal clearance of baricitinib was determined to be ∼2 L/h. The effect of a high-fat meal on baricitinib pharmacokinetics was insignificant. The pharmacodynamics of baricitinib, evaluated by the inhibition of STAT3 phosphorylation following cytokine stimulation in the whole blood ex vivo, was well correlated with baricitinib plasma concentrations. Baricitinib was generally safe and well tolerated, with no serious treatment-related adverse events (AEs) reported from either of the studies. An expected rapidly reversible, dose-related decline in absolute neutrophil count was seen with baricitinib.

Survey of POE users showed that satisfaction with POE was good. Satisfaction was more correlated with perceptions about POE's effect on productivity than with POE's effect on quality of care. Physicians and nurses constitute two very different types of users, underscoring the importance of involving both physicians and nonphysicians in POE development. The results suggest that development efforts should focus on improving system speed, adding on-line help, and emphasizing quality benefits of POE.